LMT-28
Based on 17 publication(s) in Google Scholar
LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.29%
- CAS No.: 1239600-18-0
- Formule: C17H29NO4
- Masse moléculaire:311.42
-
Stockage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) LMT-28
More- Redox Biol. 2021 Jul:43:101994. [Abstract]
- Adv Sci (Weinh). 2025 Feb;12(5):e2407398. [Abstract]
- Phytomedicine. 2026 Jan:150:157747. [Abstract]
- Stem Cell Res Ther. 2025 Nov 28;16(1):668. [Abstract]
- J Ethnopharmacol. 2026 Feb 10:356:120782. [Abstract]
- Life Sci. 2025 Sep 1:376:123749. [Abstract]
- Int J Mol Sci. 2022 Nov 9;23(22):13805. [Abstract]
- Mediators Inflamm. 2023 Jan 6:2023:9330439. [Abstract]
- Immunol Cell Biol. 2024 Oct;102(9):787-800. [Abstract]
- J Appl Toxicol. 2026 Apr 13. [Abstract]
- Cardiovasc Ther. 2025 Aug 28:2025:2852780. [Abstract]
- Cancer Manag Res. 2021 Sep 21;13:7355-7363. [Abstract]
- bioRxiv. 2026 Jun 26.
- bioRxiv. 2026 Mar 31.
- bioRxiv. 2026 Mar 20.
- SSRN. 2025 Dec 19.
- Sci Total Environ. 2022 Jul 10;829:154437. [Abstract]
Customer Validation & Images
-
Cell Migration/Invasion Assay
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
WB
Activité biologique
|
IL-6 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | CC50 |
>100 μM
Compound: 4d
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 26810262] |
| HepG2 | IC50 |
5.9 μM
Compound: 4d
|
Inhibition of gp130-IL6/IL-Ralpha interaction in human HepG2 cells assessed as inhibition of IL-6-induced STAT3 activation by luciferase reporter gene assay
Inhibition of gp130-IL6/IL-Ralpha interaction in human HepG2 cells assessed as inhibition of IL-6-induced STAT3 activation by luciferase reporter gene assay
|
[PMID: 26810262] |
| HepG2 | IC50 |
5.9 μM
Compound: 4d
|
Inhibition of STAT3 (unknown origin) transfected in human HepG2 cells assessed as inhibition of IL-6 induced STAT3 phosphorylation by luciferase reporter gene assay
Inhibition of STAT3 (unknown origin) transfected in human HepG2 cells assessed as inhibition of IL-6 induced STAT3 phosphorylation by luciferase reporter gene assay
|
[PMID: 36971365] |
| HepG2 | IC50 |
5.9 μM
Compound: 92
|
Anticancer activity against human HepG2 assessed as IL-6 induced luciferase activity
Anticancer activity against human HepG2 assessed as IL-6 induced luciferase activity
|
[PMID: 37252095] |
| TF-1 | IC50 |
7.5 μM
Compound: 92
|
Anticancer activity against human TF-1 cells assessed as cell growth inhibition
Anticancer activity against human TF-1 cells assessed as cell growth inhibition
|
[PMID: 37252095] |
LMT-28 reduces IL-6-induced luciferase activity by ~90% at a concentration of 50 μM and exhibits an IC50 value of 5.9 μM. LMT-28 (1-10 μM; 72 hours) inhibits IL-6-induced proliferation of the human erythroleukemic cell line TF-1[1].
LMT-28 (1-100 μM; 1 hour) selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:TF-1 cells (1 ng/mL IL-6-induced)
-
Concentration:1, 10, 100, 1000, 10000 nM
-
Incubation Time:72 hours
-
Result:Markedly inhibited IL-6–induced TF-1 proliferation with an IC50 value of 7.5 μM.
-
Cell Line:HepG2 cells (treated with 10 ng/mL IL-6)
-
Concentration:1, 3, 10, 30, and 100 μM
-
Incubation Time:1 hour
-
Result:Inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130.
LMT-28 (0.25 or 1 mg/kg; p.o.) ameliorates the progression of pancreatitis in mice. LMT-28 binds directly and specifically to gp130, and thereby inhibits the interaction of gp130 with the IL-6/IL-6Rα complex[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Six-week-old male DBA/1J mice (collagen-induced arthritis mice, CIA)[1]
-
Dosage:0-0.5 mg/kg
-
Administration:Oral; once daily for 15 days
-
Result:Markedly reduced the serum levels of cartilage oligomeric matrix protein (COMP) by 50%, serum amyloid P (SAP) by 55%, and anti-CII IgG by 62%.
Chemical Information
-
CAS No. 1239600-18-0
-
Appearance Viscous Liquid
-
Masse moléculaire 311.42
-
Formule C17H29NO4
-
Color Colorless to light yellow
-
SMILES
O=C1OC[C@H](C(C)C)N1C([C@@H](C)[C@H](O)C(CCCCC)=C)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
Hypoxic acclimation improves cardiac redox homeostasis and protects heart against ischemia-reperfusion injury through upregulation of O-GlcNAcylation. [Abstract]2021 Jul:43:101994. PMID: 33964586
LMT-28 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2021 Jul:43:101994. [Abstract]
LMT-28 (30 µM) blocked HA-induced elevation of O-GlcNAcylation in H9c2 cells.
-
Adv Sci (Weinh)
MAM-STAT3-Driven Mitochondrial Ca+2 Upregulation Contributes to Immunosenescence in Type A Mandibuloacral Dysplasia Patients. [Abstract]2025 Feb;12(5):e2407398. PMID: 39661729
LMT-28 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb;12(5):e2407398. [Abstract]
LMT-28 (30 µM; 37 ℃; 1 h) rescued mitochondrial dysfunction of MAD-iMSC cells treated with direct and indirect IL-6 inhibitors.
-
Phytomedicine
Unveiling poliumoside: A herbal-derived FAK kinase inhibitor with anti-proliferative and anti-metastatic efficacy. [Abstract]2026 Jan:150:157747. PMID: 41485292
LMT-28 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jan:150:157747. [Abstract]
LMT-28 (10 μM) significantly abrogated the promigratory effect of FAK in FAK-OE cells.
LMT-28 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jan:150:157747. [Abstract]
LMT-28 (10 μM) reversed the effects of FAK overexpression or knockdown on the protein level of EMT in Vector and FAK-KD H838 cells.
LMT-28 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jan:150:157747. [Abstract]
LMT-28 (10 μM) significantly abrogated the pro-proliferative effect of FAK in FAK-OE cells.
-
Stem Cell Res Ther
A serum-free adipose-conditioned medium delays stem cell senescence and maintains tissue homeostasis via IL-6/STAT3 axis suppression. [Abstract]2025 Nov 28;16(1):668. PMID: 41316397 -
J Ethnopharmacol
Network pharmacology and experimental validation identify the targets of Marsdenia tenacissima in neutrophilic asthma treatment. [Abstract]2026 Feb 10:356:120782. PMID: 41135618 -
Life Sci
PSME2 promotes malignant progression through autophagy modulation via IL-6/STAT3 signaling pathway in esophageal squamous cell carcinoma. [Abstract]2025 Sep 1:376:123749. PMID: 40404117 -
Int J Mol Sci
LPS-Induced Inhibition of miR-143 Expression in Brown Adipocytes Promotes Thermogenesis and Fever. [Abstract]2022 Nov 9;23(22):13805. PMID: 36430282 -
Mediators Inflamm
A GP130-Targeting Small Molecule, LMT-28, Reduces LPS-Induced Bone Resorption around Implants in Diabetic Models by Inhibiting IL-6/GP130/JAK2/STAT3 Signaling. [Abstract]2023 Jan 6:2023:9330439. PMID: 36643585 -
Immunol Cell Biol
TLR9-dependent dendritic cell maturation promotes IL-6-mediated upregulation of cathepsin X. [Abstract]2024 Oct;102(9):787-800. PMID: 38979698 -
J Appl Toxicol
Beryllium Sulfate-Induced Cellular Senescence via the IL-6/STAT3 Pathway to Promote Pulmonary Fibrosis. [Abstract]2026 Apr 13. PMID: 41974632 -
Cardiovasc Ther
Verteporfin Mitigates Isoproterenol-Induced Myocardial Hypertrophy by Attenuating IL-6/STAT3 in Cardiac Fibroblasts. [Abstract]2025 Aug 28:2025:2852780. PMID: 40919415 -
Cancer Manag Res
Obesity Promotes Tumor Immune Evasion in Ovarian Cancer Through Increased Production of Myeloid-Derived Suppressor Cells via IL-6. [Abstract]2021 Sep 21;13:7355-7363. PMID: 34584460 -
-
-
-
-
Sci Total Environ
Maternal DBP exposure promotes synaptic formation in offspring by activating astrocytes via the AKT/NF-κB/IL-6/JAK2/STAT3 signaling pathway. [Abstract]2022 Jul 10;829:154437. PMID: 35278568
Solvant et solubilité
DMSO : 50 mg/mL (160.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (4.01 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (4.01 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2111 mL | 16.0555 mL | 32.1110 mL | 80.2774 mL |
| 5 mM | 0.6422 mL | 3.2111 mL | 6.4222 mL | 16.0555 mL | |
| 10 mM | 0.3211 mL | 1.6055 mL | 3.2111 mL | 8.0277 mL | |
| 15 mM | 0.2141 mL | 1.0704 mL | 2.1407 mL | 5.3518 mL | |
| 20 mM | 0.1606 mL | 0.8028 mL | 1.6055 mL | 4.0139 mL | |
| 25 mM | 0.1284 mL | 0.6422 mL | 1.2844 mL | 3.2111 mL | |
| 30 mM | 0.1070 mL | 0.5352 mL | 1.0704 mL | 2.6759 mL | |
| 40 mM | 0.0803 mL | 0.4014 mL | 0.8028 mL | 2.0069 mL | |
| 50 mM | 0.0642 mL | 0.3211 mL | 0.6422 mL | 1.6055 mL | |
| 60 mM | 0.0535 mL | 0.2676 mL | 0.5352 mL | 1.3380 mL | |
| 80 mM | 0.0401 mL | 0.2007 mL | 0.4014 mL | 1.0035 mL | |
| 100 mM | 0.0321 mL | 0.1606 mL | 0.3211 mL | 0.8028 mL |
LMT-28 Related Classifications
HY-102084 Related Classifications
Powered by Bioz